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Identifying key residues of sphinganine-1-phosphate lyase for
function in vivo and in vitro
Abstract
Sphinganine-1-phosphate lyase (Dpl1p) is a highly conserved enzyme of sphingolipid metabolism that
catalyzes the irreversible degradation of sphingoid base phosphates, which are potent signaling
molecules. Sphingoid base phosphates play a vital role in cell survival, proliferation, migration, heat
stress, and cell wall integrity pathways. Little is known about the structure and regulation of Dpl1p. In
this study, we have undertaken a combined computational modeling and mutagenesis approach for
structure-function analysis of Dpl1p to discover possible modes of regulation. Our results identify
important residues for catalysis in Dpl1p and confirm it as an integral endoplasmic reticulum-resident
protein. Results further indicate that Dpl1p is most likely not regulated spatially. Importantly, we
demonstrate that Dpl1p exists as an oligomer and that polar residues in its transmembrane domain are
required for its full function in vivo but not for its localization or for its catalytic activity in vitro.
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Sphinganine-1-phosphate lyase (Dpl1p) 
is a highly conserved enzyme of 
sphingolipid metabolism that catalyzes the 
irreversible degradation of sphingoid base 
phosphates which are potent signaling 
molecules. Sphingoid base phosphates play 
a vital role in cell survival, proliferation, 
migration, heat stress and cell wall integrity 
pathways. Little is known about the 
structure and regulation of Dpl1p. In this 
study we have undertaken a combined 
computational modeling and mutagenesis 
approach for structure-function analysis of 
Dpl1p to discover possible modes of 
regulation. Our results identify important 
residues for catalysis in Dpl1p and confirm 
it as an integral ER resident protein. 
Results further indicate that Dpl1p is most 
likely not regulated spatially. Importantly, 
we demonstrate that Dpl1p exists as an 
oligomer and that polar residues in its 
transmembrane domain are required for its 
full function in vivo, but not for its 
localization or for its catalytic activity in 
vitro. 
 
INTRODUCTION 
 
Sphingoid long-chain base-1-phosphates 
(LCBPs) are intermediates in the sphingolipid 
metabolic pathway and have emerged as key 
signaling molecules. In mammals, 
sphingosine-1-phosphate (S1P) mostly through 
binding to cell surface receptors promotes cell 
survival, proliferation, migration, 
angiogenesis, inhibits apoptosis and regulates 
lymphocyte trafficking (1,2). The involvement 
of LCBPs in diverse essential cellular 
processes requires a precise control and 
regulation of their intracellular and 
extracellular levels. Moreover, the potential 
role of LCBPs in disease pathogenesis makes 
the metabolic enzymes responsible for their 
regulation attractive targets to study. One such 
key enzyme is sphinganine-1-phosphate lyase 
(Dpl1p). This yeast homologue of mammalian 
sphingosine-1-phosphate lyase 1 (SPL) 
catabolizes LCBPs to ethanolamine phosphate 
and an alkyl aldehyde, which is the only 
irreversible reaction in the sphingolipid 
pathway. The importance of this particular 
reaction is further underscored by the fact that 
it is the only exit point that connects 
sphingolipids to other metabolic pathways as 
the products of the reaction can serve as 
precursors to phospholipid metabolism. Thus 
like SPL, Dpl1p is in a vital position as it can 
regulate the flux of precursors between the 
sphingolipid and the phospholipid metabolic 
pathways. In fact, flux through sphingolipid 
pathway and the end products of the lyase 
reaction serve as a major source of 
ethanolamine for Leishmania contributing to 
infectivity and therefore SPL is also a 
candidate target for treatment of Leishmania 
diseases (3).   
Mammalian SPL has been shown to be 
involved in tissue integrity, reproduction, 
normal development, cell survival, immunity 
and mediates cellular response to stress (4-7). 
SPL is indicated to be a tumor suppressor and 
hence is a putative drug target for cancer 
treatment regime (6). In the yeast 
Saccharomyces cerevisiae, Dpl1p is 
instrumental in the heat shock response, 
diauxic shift and calcium mobilization (8-10).  
Little is known about the structural 
features of SPL or Dpl1p and their regulation 
in the cell. The high conservation of SPL 
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throughout evolution makes it reasonable to 
study Dpl1p, the yeast enzyme, to gain more 
insights into SPL. Both are predicted to be 
integral membrane proteins located in the 
endoplasmic reticulum (11). We constructed a 
structural model of Dpl1p from which we 
predicted and tested important features of the 
protein by site-directed mutagenesis and 
enzyme characterization. The sequence of 
Dpl1p encodes 589 amino acid residues and is 
predicted to possess a single transmembrane 
segment (spanning residues 59-81 according to 
TMHMM (12)), followed by a large soluble 
domain, responsible for the catalytic activity, 
which was proposed by Van Veldhoven and 
Mannaerts (1991) to be located in the 
cytoplasm. This finding was later confirmed 
by a topology study carried out by Ikeda (13) 
on mouse SPL. It is therefore reasonable to 
conclude that residues 1-58 of the Dpl1p 
sequence reside in the endoplasmic reticulum 
(ER) lumen. The predicted topology of Dpl1p 
is shown in Fig. 1A.  
Bioinformatic analysis of the cytoplasmic 
region of Dpl1p shows that a large part of it is 
distantly related to the sequence of the PLP-
dependent enzyme GadB, a bacterial 
glutamate decarboxylase. In fact, Dpl1p 
groups with GadB and related enzymes in the 
PFAM domain database. These facts prompted 
us to attempt parsed homology modelling of 
the active site region of Dpl1p. Based on the 
model and on the biochemistry of PLP-
dependent enzymes, we were able to rationally 
design Dpl1p mutants for functional analysis.  
In our study we validated the structural 
model by experiment. Furthermore, we carried 
out a mutagenesis study to investigate the role 
of the luminal and transmembrane domain 
(TMD) hitherto considered redundant, in 
Dpl1p function and spatial regulation. Our 
results show that Dpl1p is statically retained in 
the ER. Most intriguingly, Dpl1p forms homo-
oligomers whose detection depends upon the 
presence and sequence features of the 
transmembrane domain. These features are 
required for optimal activity in vivo, but not 
for catalytic activity in vitro even though they 
have no influence on protein localization to the 
endoplasmic reticulum. We speculate about 
possible explanations for this intriguing 
finding. 
 
EXPERIMENTAL PROCEDURES 
 
Yeast strains and plasmids-  The yeast 
strains used in this study are JS16, MATα 
leu2-3,112 trp1 ura3-52 his3 ade8 ras1::HIS3 
dpl1Δ::KanMx, SGP3, MATα leu2-3,112 trp1 
ura3-52 his3 ade8 ras1::HIS3 (14), RH4863 
MATα lcb3Δ::KanMx dpl1Δ::KanMx ura3 
leu2 his4 ade2 bar1, pLCB3::URA3 (PCR 
amplified genomic LCB1 cloned into 
YCplac33(15)) and RH4564 MATα 
dpl1Δ::KanMx ura3 leu2 his4 bar1 (our 
laboratory collection). In JS16 erg6::hph 
(hygromycin) was disrupted with gene 
replacement cassette using standard 
procedures (16). PEP4 was deleted in JS16 
strain by using the plasmid pTS15 (17). 
pRS415 and pRS416 (New England Biolabs) 
were used to express DPL1 from its own 
promoter. pESC-URA (Stratagene) was used 
to overexpress DPL1 under a galactose-
inducible promoter. pESC-Dpl1-Flag was 
constructed by cloning 1.77-kb EcoRI-SpeI 
DPL1 PCR amplified fragment in pESC-URA. 
pRS415 Dpl1-Flag tagged construct was 
generated by cloning PCR amplified 2.28-kb 
XbaI-PstI containing the 0.5-kb DPL1 
promoter region in XbaI-PstI site in pRS415 
and by subsequently subcloning the 0.5-kb 
StuI-PacI fragment containing FLAG from 
plasmid pESC-Dpl1-Flag. pRS415 Dpl1-
Venus was generated by cloning 0.71-kb SpeI-
HindIII PCR amplified fragment in all the 
Dpl1-Flag plasmids. The plasmids constructed 
in this study are listed in Table II.  
DPL1 mutants were constructed by site 
directed mutagenesis following standard 
procedures. All constructs were verified by 
sequencing. 
Phytosphingosine sensitivity Dpl1p 
functionality test-  Cells from overnight 
culture in SD medium were serially diluted 10-
fold (for the last spot 1:5 dilution) and spotted 
on SD medium containing either ethanol 
(carrier vehicle) or 50µM phytosphingosine 
(4-OH sphinganine, PHS). After three days 
incubation at 300C plates were imaged. 
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3 
Pulse chase experiment- Pulse chase 
analysis was performed essentially as 
described in (18).  Briefly, 10 OD600 units of 
logarithmic phase cells expressing FLAG 
tagged wild-type or mutant Dpl1p were pulsed 
with 50µCi/ml of 
[35S]methionine/[35S]cysteine mix (EasyTagTM 
EXPRESS[35S] mix from PerkinElmer Life 
Sciences) for 6 min at 300C. The chase was 
initiated by adding 1/100 volume of a mixture 
of 0.3% methionine/cysteine in 0.3 M 
(NH4)2SO4. At specific time intervals aliquots 
were removed and the reaction terminated by 
adding NaF/NaN3 to a 10mM final 
concentration. Dpl1p was immunoprecipitated 
using Flag beads. Similarly, the Gas1p control 
was immunoprecipitated by anti-Gas1p 
antibody and protein A-sepharose beads. The 
proteins were eluted into TEPI (100mM Tris-
HCl pH 7.5, 10mM EDTA, protease 
inhibitors) containing 1% SDS buffer, 1% 2-
mercaptoethanol by boiling at 95°C for 10 
min. Eluates were equally divided into three 
immunoprecipitation reactions; the first with 
anti-Flag Ab and protein G-Sepharose beads 
(GE healthcare biosciences AB); the second 
with α-1,3-mannose Ab and protein G-
Sepharose beads and the third with protein G-
sepharose beads alone. Samples were 
separated by SDS-PAGE and analyzed by 
Cyclone Storage Phosphor system (Packard). 
Cell extract preparation- Cells were 
resuspended as 100 OD600 units of cells/ml in 
lysis buffer (50mM Tris pH7.5, 150mM NaCl, 
20% glycerol, 1mM PMSF, 1X protease 
inhibitor cocktail (Sigma)). After glass bead 
lysis and removal of cell debris by 
centrifugation, protein concentration was 
determined by BIO-RAD protein assay.  
Endoglycosidase H (EndoH) treatment- 
Cells grown in selective SD medium were 
harvested in mid-logarithmic phase. Cells 
were lysed and processed as previously 
described (19). 40µl of cell extract was treated 
with 25mU of EndoH (Roche) for 1 hour at 
370C. Boiled samples were separated by SDS-
PAGE and detected by Western blotting(20). 
Protein purification and sphinganine-1P 
lyase assay- FLAG tagged purification was 
performed as described previously (21) with 
the following changes. Cells bearing DPL1-
FLAG on overexpression plasmids were grown 
to exponential phase in selective S raffinose 
2% (w/v), glycerol 3% (w/v) minimal medium 
and expression was induced by 2% galactose 
for 4 hours. Cells were broken in lysis buffer 
with chilled glass beads. After removal of cell 
debris, NP-40 was added to a final 
concentration of 1% to the resulting 
supernatant. Binding to FLAG beads, washing 
and elution were performed as described 
before. [4,5-3H]-spinganine-1P was prepared 
from radiolabeled [4,5-3H]-sphinganine (ARC, 
Saint Louis, MO) by incubation with purified 
yeast sphingosine kinase, Lcb4p (provided by 
I. Riezman, Univ of Geneva), separation by 
TLC and extraction from the plate.  The 
activity of purified wild-type and mutant 
Dpl1p proteins was assayed by incubating 
0.5μg of purified protein with 5µCi [4,5-3H]-
sphinganine-1-P at 300C for 30 min in reaction 
conditions as previously described (11). 
Proteasome inhibition and 
Cycloheximide (CHX) chase analysis- The 
experiment was carried out as described in 
(22) with minor modifications. Cells were 
grown to 1 OD600 and incubated at 300C with 
100µM MG-132 (Sigma) in dimethyl 
sulfoxide (DMSO). 12 OD600 units of cells 
were removed and added to NaN3 (final 
concentration 10mg/ml) at time points 0 and 2 
hours. For CHX chase, cells were grown 
similarly as for the proteasome inhibition 
assay. 0.5mg/ml final concentration of CHX 
(Sigma) in DMSO was added to cells. 7 OD600 
cells were removed per time point. Cell extract 
preparation was performed as described above.  
Immunoprecipitation- Cell extract was 
prepared as described above and solubilized 
by incubation at 40C for 1 hour with digitonin 
0.5% (v/v) final concentration. After 
centrifugation at 14,000 rpm, 40C for 30 min, 
the supernatant was collected. 2 mg of total 
protein were immunoprecipitated with anti-
VENUS antibody and Protein A sepharose 
beads (GE healthcare biosciences AB) or anti-
FLAG sepharose beads (Sigma). Beads were 
washed with 50mM Tris–HCl, pH 7.5, 150mM 
NaCl, 5mM EDTA 0.1% digitonin. Proteins 
were eluted by boiling in 2X sample buffer 
and analyzed by Western blotting(20).  
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Blue Native PAGE (BN-PAGE)- 
Overnight cultures were harvested at 1 OD600  
units and cells were resuspended at 100 OD600 
units/ml in NativePAGE sample buffer 
(Invitrogen) with 1mM PMSF, protease 
inhibitor cocktail (Sigma) (NativePAGE-SB). 
After glass bead lysis, samples were 
centrifuged at 13,000g for 15 min at 4°C. The 
resulting pellet was resuspended in 
NativePAGE-SB with 0.5% digitonin and 
solubilized for 30 min at 4°C. The solubilized 
sample was clarified by centrifugation at 
14,000 rpm for 30 min at 4°C. The final 
sample was prepared by adding NativePAGE 
5% coomassie G-250 (Invitrogen) to a final 
concentration of 0.125% to the solubilized 
clarified extract. Samples were separated on a 
4-16% acrylamide gradient NativePAGE 
Novex Bis-Tris gel (Invitrogen) and Western 
blotting was performed(20). 
Synthetic lethality test- RH4863 cells 
were transformed with pRS415 plasmids 
containing wild type or mutant DPL1 genes. 
Cells were grown in SD medium without 
leucine, 10 fold serial dilutions were prepared 
and cells were spotted onto agar plates 
containing SD without leucine, without uracil, 
or containing 5-fluoroorotic acid to select for 
cells that had lost the pLCB3::URA3 CEN 
plasmid.  
Fluorescence microscopy- Cells bearing 
DPL-VENUS plasmids were grown to 
exponential phase in minimal selective 
medium. Fluorescence images were obtained 
using YFP filter on an Axio Imager Z1 
microscope. 
Quantification of cellular PHS- 1P- JS16 
cells carrying pRS415 series plasmids with 
wild type or mutant DPL1 were grown to late 
log phase in SD without leucine. 40 OD600 
units of cells were harvested and washed once 
with SD minus leucine. Cells were 
resuspended in SD minus leucine containing 
20 μM sphinganine (Avanti Polar Lipids) and 
incubated for 10 min at 30°C. TCA was added 
to 5% final concentration and the cells were 
cooled and harvested by centrifugation. The 
cells were washed once with cold 5% TCA 
and once with cold water. Cell pellets were 
frozen and 10 μg each of C17 sphingosine and 
C17 sphingosine 1-phosphate (Avanti Polar 
Lipids) were added before extraction using 
glass beads and ethanol/ether/pyridine(23) at 
60°C, except that the samples were not 
desalted after extraction. Samples were 
analysed by HPLC-Tandem Mass 
Spectrometry as described(24) on a Varian 
320 Triple Quadrupole MS. Sphingoid bases 
were separated on a Uptisphere ODB column 
(5 μm, 1 mm x 150 mm) at a flow rate of 50 
μl/min at 30°C and data acquired using the 
following optimized transitions (C17 
sphingosine, 286>268, -17 V, C17 
sphingosine-1P, 366>250, -15 V, sphinganine 
302>282, -22V, PHS, 318>282 -24V, 
sphinganine 1P, 382>282, -18V, PHS-1P, 
398>282, -18 V). Two independent 
experiments were performed, each in 
duplicate, and each sample was analyzed at 
least three times by HPLC-MS.  Sphinganine 
was rapidly converted to PHS intracellularly 
because the former was not detected in most 
samples. Data for PHS-1P levels was corrected 
for recovery and detection by reference to the 
internal standard C17 sphingosine 1P, which 
allows a reliable relative quantification 
between samples, but does not permit an 
absolute quantification. 
Parsed homology modeling- A parsed 
homology model of Dpl1p was created based 
on the structure of E. coli GadB at low pH 
(PDB code 1PMM) using the program 
Modeller (v7) (25). The PLP cofactor was also 
modeled into the active site and the Schiff 
base linkage to K380 optimized in a final 
energy-minimization step with CNS (26). 
Only the residues in the active site region and 
the cofactor, which aligned very clearly with 
the template and other SPL and Gad sequences 
in multiple sequence alignments, were retained 
in the final model. 
 
RESULTS 
 
DPL1 parsed homology modeling and 
mutational testing- According to the PFAM 
database (27), Dpl1p and related SPLs from 
different eukaryotes belong to the PLP-
dependent aminotransferase superfamily clan. 
More specifically, their catalytic domain is a 
pyridoxal-dependent decarboxylase conserved 
domain (PF00282). A BLAST search of 
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Dp11p versus the PDB database identifies E. 
coli GadB (28,29) as the top hit, with a 
sequence identity of 23% over a 251-residue 
long aligned region. Based on the two 
representative structures of PF00282, GadB 
and Dopa-decarboxylase (30), one can assume 
that the quaternary assembly of Dpl1p is either 
dimeric (like Dopa-decarboxylase) or a 
multiple of dimeric units (like GadB, a 
hexamer which is trimer of dimers) (Fig. 1B). 
We analyzed the possibility that Dpl1p is part 
of a large molecular weight complex by Blue 
Native PAGE (BN-PAGE) and Western 
blotting (Fig. 8B). Both Dpl1p-Venus and 
Dpl1p-FLAG tagged proteins migrated in BN-
PAGE gels at an apparent molecular size of 
over 300,000 daltons confirming that it is part 
of a large complex. Co-precipitation 
experiments (see below) prove that Dpl1p 
subunits self-associate. It is not possible to 
determine whether the Dpl1p oligomer is a 
tetramer or a hexamer from our data, a 
problem that is rendered more difficult to 
solve by the obligatory presence of detergent 
to keep the enzyme soluble. 
To determine if the luminal domain of 
Dpl1p has any role in its function, we 
generated an NΔ57 truncation mutant lacking 
the entire luminal domain, which as mentioned 
above, is predicted by TMHMM to span 
residues 1 to 58. NΔ57 was tested for its 
ability to complement a dpl1Δ mutant in the 
presence of phytosphingosine. Under standard 
laboratory growth conditions, Dpl1p is not 
essential, but is required for yeast cells to grow 
on a medium containing an elevated 
concentration of PHS (50µM was used in this 
study). PHS is cytotoxic at high 
concentrations. This mutant was completely 
inactive in the in vivo complementation assay 
(Fig. 2A). The steady state level of the NΔ57 
mutant protein was nearly undetectable (Fig. 
2B). A partial or total absence of the luminal 
domain could affect the steady state level of 
Dpl1p by modulating protein stability. We 
further investigated this possibility by 
constructing other truncation mutants as 
discussed later. 
One of the major aims of this study was 
to identify important residues for the structural 
integrity, catalytic activity and substrate 
binding of Dpl1p. To this end, a parsed 
homology model of the Dpl1p active site 
region was created based on the structure of 
GadB and on multiple sequence alignments of 
Dpl1p and SPLs. Also information from 
PF00282 was taken into account. The model 
(Fig. 1C) shows that the cofactor, covalently 
linked to K380, is sandwiched between C344 
and H268. The pyridinium nitrogen of the 
pyridoxal 5’-phosphate ring interacts 
electrostatically with the side chain 
carboxylate of D342. The phosphate moiety of 
the cofactor is held in place by a network of 
hydrogen bonding interactions with the main 
chain amides of G235, T236, the side chain 
imidazole of H379 and the side chain hydroxyl 
of S422.  
Several mutants were designed based on 
the active site homology model: H268A was 
aimed at impairing PLP binding via removal 
of the stacking aromatic ring of H268. Two 
Lys to Ala mutants, K380A and K386A, were 
assumed, respectively, not to be able to form 
an internal aldimine link with the cofactor 
(removal of the catalytic lysine side chain) and 
to be impaired in substrate binding (removal of 
a Lys side chain which is near the region 
where the phosphate moiety of LCBP is 
supposed to bind). All of the above mutants 
were created and tested for their ability to 
complement the dpl1Δ mutant in presence of 
PHS. As predicted, the mutants did not 
complement the dpl1Δ deletion mutant and 
therefore we conclude that they exhibit very 
low or no activity (Fig. 2A). The K380 and 
K386 mutants exhibit normal steady-state 
protein levels, but they lack function (Fig. 2B). 
We confirmed that the absence of function in 
the K380 and K386 mutants is due to a lack of 
enzymatic activity by using an in vitro enzyme 
activity assay (Fig. 2C). Another residue, 
C344, is a PLP-stacking residue and may be 
the nucleophilic Cys that was proposed to 
attack the C3 carbon of the substrate (31). The 
mutant Dpl1p-C344A was partially active in 
the in vivo complementation assay (Fig. 2A) 
and present at almost normal levels (Fig. 2B). 
Interestingly, the residue corresponding to 
C344 in mammalian SPL, C317, has been 
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mutated to Ser and exhibits a severe loss of 
activity in vitro (32). 
An additional histidine mutant, H340 was 
designed based on the consideration that a 
fully conserved residue in members of the 
PF00282 family, H241 of GadB, has been 
proposed to play a critical structural role for 
the stability of this group of proteins (33). We 
created this mutant and it was also inactive for 
complementation (Fig. 2A). Steady state levels 
of this mutant protein were substantially lower 
than the wild type, suggesting that the mutant 
protein is indeed unstable, which is consistent 
with the proposed function of this residue (Fig. 
2B). 
Two additional mutants, Y554A and 
Y554F, belonging to the C-terminal region of 
Dpl1p, were designed by analogy with GadB. 
Namely, the C-terminal region of GadB, 
which encompasses residues 452-466, does 
not belong to the PF00282 domain core and is 
flexibly disordered at low pH. This region can 
take up an ordered conformation and insert 
into the active site at neutral pH, thus 
inhibiting the enzyme. The inhibition has been 
recently shown to take place via a covalent 
linkage between the distal side chain nitrogen 
of H465 (the penultimate residue of the 
protein) and the C4` atom of the cofactor (29). 
A Ka/Ks ratio analysis performed with 
SELECTON (34) on 44 nucleic acid 
sequences coding for GadB proteins (G. 
Capitani, unpublished) revealed that the C-
terminal region of GadB (residues 452-466), 
which is flexibly disordered at low pH, 
possesses only one residue under strong 
purifying selection and this is H465, followed 
by a small residue, T466. 
A similar Ka/Ks ratio analysis was 
carried out on 10 coding sequences of Dpl1p 
and related SPLs. The C-terminal region of 
Dpl1p, encompassing 46 residues if one uses 
the GadB domain boundaries, was inspected to 
see if it exhibited a feature similar to the 
H465-T466 region of GadB. Thus, the search 
aimed at His, Tyr or Lys residues (capable of 
acting as nucleophiles and of exchanging 
protons) which were both under strong 
purifying selection and were followed by a 
small residue like Gly, Ser, Ala or Thr. One 
such residue was Y554 (followed by G555). 
We constructed two mutants, Y554A and 
Y554F, which showed partial activity in the in 
vivo complementation tests, even though the 
protein is present in normal amounts at steady-
state (Fig. 2B), suggesting that this residue is 
important, but not absolutely required (Fig. 
2A). It is quite possible that this residue plays 
a regulatory role.  
Dpl1p is statically retained in the ER- 
Dpl1p is reported to localize to ER (35,36). 
We observed Dpl1p tagged with the yellow 
fluorescent protein variant Venus (functional 
in the in vivo complementation test – data not 
shown) by direct fluorescence microscopy. 
Dpl1p-Venus displayed cortical and 
perinuclear ER localization consistent with 
previous studies (Fig. 3A). ER retention can be 
mediated by static retention or continuous 
retrieval from an early Golgi compartment. 
Dpl1p is glycosylated (see below) and to 
measure whether Dpl1p reaches the Golgi 
compartment we tested if its N-linked glycan 
could be modified in the cis-Golgi 
compartment by α-1,6 mannosylation. By 
pulse chase analysis, no α-1,6 mannosylation 
could be detected on Dpl1p after 60 minutes 
suggesting that the enzyme is not transported 
to the cis-Golgi within this time frame (Fig. 
3B). Under the same conditions we were able 
to detect α-1,6 mannosylation of a control 
protein, Gas1p. These results indicate that 
Dpl1p is retained statically in the ER (Fig. 
3B). 
Dpl1p is glycosylated and the luminal 
domain is essential for enzyme stability- We 
observed that Dpl1p migrates as a doublet 
upon overexpression on SDS-PAGE (our 
unpublished data) and the Dpl1p sequence has 
a classical N-linked glycosylation motif Asn-
X-Thr(Ser) in the N-terminus. To determine if 
the protein is glycosylated, we created a 
mutant protein (Dpl1N6Ap), treated the wild 
type protein with endoglycosidase H (EndoH) 
and analyzed their migration by SDS-PAGE. 
Both mutation and EndoH treatment caused an 
increase in protein mobility demonstrating that 
Dpl1p undergoes N-linked glycosylation (Fig. 
4B). Glycosylation can modulate protein 
function/activity by affecting conformation, 
stability and targeting (37). We checked the 
role of Dpl1p glycosylation by in vivo 
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7 
complementation and results show that 
glycosylation is dispensable for Dpl1p 
function (Fig. 4C). 
Like SPL, Dpl1p is predicted to be a type 
I membrane protein (Fig. 1A). It has been 
shown that the TMD of recombinant SPL is 
important for membrane association but not 
for in vitro activity (32). A requirement for the 
TMD of SPL in vivo has not been reported in 
the literature. We investigated the in vivo 
requirement of the TMD and the luminal 
domain (as mentioned earlier). To this end, we 
generated several truncations in the N-terminal 
domain of Dpl1p schematically represented in 
Fig. 4A. An NΔ54 truncation mutant bearing 
some additional residues after the TMD of 
Dpl1p to facilitate insertion into the ER 
membrane was constructed. This mutant also 
demonstrated no complementation on PHS 
plates and a lower steady state level, with the 
mutant protein being barely detectable (Figs. 
4C and 4D). On the other hand, the NΔ31 
truncation mutant was functional and stable. 
This suggests that the 32-54 amino acid region 
might play an important role in the stability of 
Dpl1p in the ER membrane. As Dpl1p does 
not contain a cleavable signal sequence for ER 
insertion, it might be that this mutation affects 
membrane insertion or the subsequent 
topology of the inserted protein. Improper 
insertion would most likely lead to instability. 
Dpl1p has an atypical transmembrane 
domain with many polar residues- The TMD 
of Dpl1p is predicted to encompass amino acid 
residues from 59 to 81 (Fig. 5A). Deletion of 
the entire luminal domain and TMD, NΔ81, 
resulted in lack of function in vivo (Fig. 5B). 
Like the NΔ54 and NΔ57 mutants, nearly 
undetectable steady state levels are likely to be 
the cause of lack of function (Fig. 5C). 
Interestingly, the predicted TMD of Dpl1p 
possesses three polar and one charged residue 
(Fig. 5A). To identify the possible function of 
these residues, we mutated C65, K67, S70 and 
N71 individually, in pairs and all of them 
together to leucine, a more common 
component of TMDs. K67L complemented the 
dpl1Δ although not quite as efficiently as the 
wild-type enzyme, while the double mutants 
K67LS70L, S70LN71L both showed similar 
partial complementation on PHS plates(Fig. 
5B). Strikingly, the quadruple mutant did not 
complement at all (Fig. 5B). The lack of 
complementation on PHS plates cannot be 
explained by protein instability in this case 
because the quadruple mutant was expressed 
at the same level as the wild-type protein (Fig. 
5C). Therefore, the polar residues in the 
transmembrane domain are required for Dpl1p 
function in vivo. This mutant is recessive as it 
did not confer a phenotype when expressed in 
the presence of the wild-type protein (Fig. 
5D). 
In order to provide additional assays for 
the in vivo function of the mutants affecting 
the luminal and transmembrane regions we 
performed two assays. Dpl1p is one of the two 
major enzymes that degrade PHS-1P, which is 
apparently toxic to cells in high amounts(38). 
The other enzyme is the sphingoid base 
phosphate phosphatase, for which the major 
activity is encoded by LCB3. Mutation of 
DPL1 and LCB3 is synthetically lethal, but 
cells can be maintained alive by expressing 
LCB3 from a URA3 containing plasmid. We 
introduced our constructs into a dpl1 lcb3 
double mutant containing pLCB3::URA3 and 
screened for the ability of the cells to lose the 
LCB3 plasmid on 5-fluoroorotic acid plates, a 
measure of the ability of the Dpl1p mutants to 
degrade sphingoid base phosphates. These 
assays (Fig 6A) agree well with the PHS plate 
assay results. 
We also assessed the in vivo activity of 
the Dpl1p constructs more quantitatively by 
measuring the intracellular PHS-1P 
concentrations relative to wild type cells by 
HPLC tandem mass spectrometry. To increase 
cellular levels of sphingoid bases we added 
external sphinganine for 10 min then stopped 
all reactions with TCA. Sphingoid bases were 
extracted and quantified by mass 
spectrometry. The amount of sphingoid bases 
phosphates in the mutant strains is expressed 
as a fold increase over wild type cells. As can 
be seen (Fig 6B) cells carrying the plasmid 
without insert showed a 4 fold rise in PHS-1P, 
whereas the Δ31dpl1 mutant behaved like wild 
type cells. The Δ81dpl1 mutant cells behaved 
like the dpl1 null. The point mutants in the 
TMD showed intermediate results, which are 
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8 
consistent with the plate assays if one assumes 
that there is a threshold level of activity that is 
required in the presence of excess PHS or 
when LCB3 is absent. This threshold would be 
situated in between the activities of the K67L 
and CSKN mutant levels. In any event, the MS 
results show that the activity in vivo of the 
CSKN and K67L mutants are compromised. 
It has been previously reported that 
charged residues in TMDs are important for 
ER retention (39,40). The defect in the 
quadruple mutant could be due to loss of ER 
retention and subsequent mislocalization.  To 
determine if the quadruple mutant exits the ER 
and reaches the cis-Golgi where its N-linked 
glycan would be remodeled by α-1,6 
mannosylation, we performed pulse chase 
analysis. No α-1,6 mannosylation could be 
detected within the 60 minutes time frame of 
the experiment (Fig. 3B).  Hence, it does not 
appear that the lack of complementation is due 
to a defect in ER retention. We further 
checked the subcellular localization of Dpl1p 
mutants tagged with Venus by direct 
fluorescence microscopy. All mutants except 
NΔ54 showed a cortical and perinuclear ER 
localization like wild-type Dpl1p (Fig. 6A).  
The mutant NΔ54, detected only at increased 
camera sensitivity because of its low steady 
state level, does not show the characteristic ER 
pattern and seems to form aggregates of 
unknown localization. To test if the punctate 
structure observed for NΔ54 represents 
molecules transported from the ER, we 
performed a localization study in sec18-ts cells 
which are defective in ER to Golgi transport at 
370C (restrictive temperature). Localization of 
NΔ54 in the sec18-ts was not altered after 1 
hour incubation at the restrictive temperature 
indicating that the punctate structure observed 
is not a product of transport from the ER (our 
unpublished data). This indicates that the 
luminal domain of Dpl1p is also important for 
its proper localization to the ER.  The 
complete lack of function displayed by the 
NΔ54 mutant in vivo is probably due to a 
combined effect of its low steady state levels 
and its mislocalization, since another mutant 
(K67S70_LL) with lower steady state levels, 
but localized to ER, is partially functional.  
There is no obvious ER retention signal 
in the Dpl1p sequence and the quadruple 
mutant comprising all of the polar residues in 
the TMD does not leave the ER, so there could 
be redundant retention signals; one in the 
TMD and one in the luminal domain. To test 
this idea we combined the NΔ31 truncation 
mutant with the quadruple mutant and checked 
functionality, stability and localization. This 
mutant did not complement, but was fairly 
stable and remained localized in the ER (Figs. 
6C and D). In all of our constructs where 
Dpl1p was stable we found it localized in the 
ER and never observed it in other 
localizations, even at various stages of growth 
(our unpublished data). In yeast it is evident 
that the major sphingosine kinase Lcb4p is 
regulated spatially in the cell (41-43) as is 
mammalian sphingosine kinase 1 (44). But the 
two yeast enzymes that dephosphorylate 
LCBPs, Lcb3p and Ysr3p, both have also been 
shown to be localized to the ER membrane 
like Dpl1p (45,46). Therefore, it is clearly 
important to understand how Dpl1p and the 
LCBP phosphatases can act on LCBPs that 
have been generated elsewhere than in the ER.  
Unstable Dpl1p mutant proteins are 
degraded in the ER- Several of the 
mutations/truncations we created seem to 
render Dpl1p unstable. To verify this we 
performed a cycloheximide (CHX) chase 
assay with the NΔ81 truncation mutant, which 
displays a low steady state level. The amount 
of protein for NΔ81 was much lower both at 
time point 0 and after 60 min of CHX 
treatment, NΔ81 showed a 50% decrease in 
amount while wild-type Dpl1p amount was 
altered only by 20% (Fig. 7A). This instability 
may be either due to transport through the 
secretory pathway and degradation in the 
vacuole or degradation directly via the 
proteasome. Unstable sphingoid base kinase 
seems to be degraded in the vacuole (42,47). 
To resolve the above issue, we created a 
dpl1Δpep4Δ mutant strain that lacks vacuolar 
protease activity. Reducing vacuolar protease 
activity did not render the mutants functional 
nor were they stabilized (Figs 7B and C). This 
suggests that the Dpl1p mutants might be 
degraded by the proteasome. To test this, we 
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9 
treated dpl1Δerg6Δ (dpl1Δerg6Δ was 
generated to facilitate uptake of the MG-132) 
bearing DPL1 plasmids with MG-132, a 
specific proteasome inhibitor and examined 
the stability of FLAG tagged NΔ54 and 
NΔ81Dpl1p. MG132 seemed to partially 
stabilize these mutants, indicating that they 
may be degraded by the proteasome (Fig. 7D). 
Oligomerization and Dpl1p function in 
vivo- Since mislocalization is not responsible 
for the functional defect in the TMD mutants 
and even though this region is far from the 
active site of the enzyme, it could be that the 
enzymatic activity of the TMD mutants is 
affected. To verify this hypothesis, we 
performed an enzyme activity assay with the 
TMD mutants after overexpressing and 
purifying them individually. Both NΔ81 and 
K67L mutants displayed slightly lower activity 
than wild-type Dpl1p while the quadruple 
mutant showed a somewhat more substantial 
activity loss (Fig. 8A). Therefore, the 
transmembrane domain does appear to play a 
role for lyase activity. However, this partial 
loss in activity cannot account for the 
complete lack of function in vivo. Hence, we 
surmised that the polar residues in the TMD of 
Dpl1p might play another critical role. In some 
cases, like in the Hepatitis C virus, polar 
residues are important for complex formation 
(39). Our modeling study predicts Dpl1p to be 
a dimer or multiple of dimers, which is 
consistent with BN-PAGE data (Fig. 8B). 
Thence, we investigated the complex 
formation ability of the quadruple and K67L 
mutants by a co-immunoprecipitation method. 
We found that wild-type FLAG tagged Dpl1p 
co-precipitates with wild-type Venus tagged 
Dpl1p and vice versa. The mutant K67L was 
co-precipitated substantially less efficiently 
while the quadruple mutant was not 
precipitated at all (Figs 8C and D). These data 
show that the transmembrane region is 
important for efficient complex formation. As 
measuring complex formation by co-
precipitation is a very stringent technique we 
also examined the complex status of the 
quadruple mutant by BN-PAGE and found 
that Dpl1CKSN_LLLL could be detected in a 
complex although much less efficiently.  
 
  
DISCUSSION 
 
Our experiments clearly demonstrate that 
Dp11p forms higher order complexes and 
Dpl1CKSN_LLLL seems to do so less 
efficiently. We speculate that the failure to 
self-associate into a large quaternary assembly 
may be important for Dpl1p function in vivo. 
Higher order assembly is not absolutely 
mandatory for enzymatic activity as the 
protein remains active in the in vitro assay, 
even though its activity is compromised in 
vivo. This rather surprising finding suggests 
that the TMD of Dpl1p plays a role in function 
that might not be directly required for catalytic 
activity. The role of the TMD in 
oligomerization does not seem to be important 
for stabilizing the enzyme structure, since the 
TMD quadruple mutant protein appears to be 
quite stable. 
The precise role of the TMD is not clear 
from our data but one highly interesting 
suggestion would be that the TMD itself 
and/or enzyme oligomerization is important 
for presentation of the substrate to the enzyme 
in the membrane. The properties of the Dpl1p 
substrate are rather particular comprising a 
large hydrophobic domain that should deeply 
penetrate the lipid bilayer and a very 
hydrophilic ethanoloamine phosphate group. 
One could also speculate that the lysine 
residue near to the cytoplasmic side of the 
predicted TMD might form an ion pair with 
the phosphate of the LCBP helping to position 
the substrate for the enzymatic reaction, which 
would take place at the hydrophobic-
hydrophilic interface of the membrane. This 
rather precise positioning information would 
be less important for the in vitro activity of the 
enzyme which takes place in the presence of 
detergent.  
We have also shown that membrane 
association of the enzyme is not required for 
catalytic activity in vitro, but is absolutely 
required for activity in vivo. It is also possible 
to imagine that a particular as yet undefined  
property of the membrane interaction is 
required for optimal activity in vivo. 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
10 
In addition to the surprising role of the 
TMD, we have identified by parsed homology 
modeling critical residues in the Dpl1p active 
site, which we have subsequently validated by 
experiments. Our results show that Dpl1p is 
glycosylated, but glycosylation does not seem 
to play an important functional role. The 
luminal domain of Dpl1p is important for 
protein stability. Our results also indicate that 
Dpl1p is not likely to be regulated spatially 
and its ER localization is important for its 
function, even though it is likely that its 
substrate can be generated elsewhere in the 
cell. Interestingly, it seems that delivery of 
sphingoid base phosphates to the phosphatase, 
Lcb3p, requires formation of the sphingoid 
base phosphates on the ER membrane(48), at 
least for productive dihydroceramide 
formation. If the same is true for Dpl1p, then 
sphingoid bases phosphates formed at other 
locations than on the ER membrane would 
constitute a distinct intracellular pool of these 
molecules not accessible to the major activities 
that degrade them. 
Our structural modeling and mutagenesis 
study might be useful for designing inhibitors 
that affect the enzyme active site. FTY720, a 
known immunosuppressant which has already 
been shown to be pharmaceutically useful has 
also been found to inhibit SPL (49). The 
results from this study might also help to 
identify genetic alterations that lead to loss of 
enzyme function without affecting protein 
stability or activity and in the future may serve 
as genetic markers for predisposition to 
disease.  
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FIGURE LEGENDS 
 
Fig. 1. Dpl1p is an oligomer. (A) Schematic representation of Dpl1p predicted topology. 
Dpl1p is predicted to be a type I membrane protein with a short luminal domain and a 
large cytoplasmic domain containing the active site (B) The basic unit of Dpl1p is a 
dimer.  Proteins of the PF00282 PFAM family are constitutive homodimers (like Dopa-
decarboxylase, top panel) or higher oligomers resulting from the assembly of 
homodimers (like GadB, a trimer of dimers, bottom panel). Both Dopa-decarboxylase 
(1JS6) and GadB (1PMM) are shown in stereo cartoon representation and colored by 
chain. Their PLP cofactors appear in spacefill representation (yellow). (C) Stereo view of 
the modeled Dpl1p active site.  
 
Fig. 2. Analysis of predicted important residues for structure and activity of Dpl1p. (A) In 
vivo complementation of DPL1-FLAG mutants constructed as predicted by the model. 
(B) Stability test. JS16 (dpl1Δ) cells carrying plasmids expressing FLAG tagged Dpl1p or 
Dpl1p mutants under own promoter 1: vector; 2: DPL1; 3: NΔ57DPL1; 4: H268A; 5: 
H340A; 6: C344A; 7: K380A; 8: K386A; 9:  Y554A; 10: Y554F were analyzed. Results are 
shown from one experiment, but are representative of three separate experiments. (C) 
Activity test of Dpl1p active site mutants. The average and standard deviation for three 
independent determinations is shown.  
 
Fig. 3. Dpl1p shows a static localization to ER (A) Localization of Dpl1p-Venus. (B) 
Dpl1p and CKSN_LLLL mutants possible recycling between ER and Golgi was assessed 
by [35S] Met/Cys pulse labeling and chase analysis.  
 
Fig. 4. Role of glycosylation and luminal domain of Dpl1p (A) Schematic representation 
of Dpl1p and various truncation constructs generated in this study (B) Dpl1p is 
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14 
glycosylated. Glycosylation status of Dpl1p was determined by treatment with 
endoglycosidase H treatment and compared with the glycosylation mutant N6A. (C) In 
vivo complementation of Dpl1p glycosylation and luminal domain truncation mutants. 
(D) Stability test. JS16 (dpl1Δ) cells carrying plasmids expressing FLAG tagged Dpl1p 
or Dpl1p mutants under own promoter 1: vector; 2: DPL1; 3: NΔ31DPL1; 4: NΔ54DPL1 
were analyzed. 
 
Fig. 5. Role of transmembrane domain of Dpl1p (A) Schematic representation of Dpl1p 
structure including the sequence of the transmembrane domain with polar residues in 
bold. (B) In vivo complementation of Dpl1p transmembrane domain mutants. (C) 
Stability test. JS16 (dpl1Δ) cells carrying plasmids expressing FLAG tagged Dpl1p or 
Dpl1p mutants under own promoter 1: vector; 2: DPL1; 3: NΔ81DPL1; 4: K67L; 5: 
CKSN_LLLL; 6: K67S70_LL; 7: S70N71_LL were analyzed. (D) Dominance test of 
CKSN_LLLL mutant.  
 
Fig. 6. Function of Dpl1p mutants in vivo. (A) Strain RH4863 carrying the designated 
wild type DPL1,  mutant dpl1 alleles or empty vector were 10 fold serially diluted and 
spotted onto SD plates without leucine or on SD plates with uracil and 5-fluororotic acid 
(5-FOA). Only strains with a functional Dpl1p can lose the plasmid and grow on 5-FOA 
plates. The colonies were allowed to grow for 2 days and then photographed. (B) PHS-1P 
was quantified in wild type and mutant cells (plasmid borne DPL1 genes) by HPLC 
tandem mass spectrometry and the amount was compared to wild type cells (set to 1). 
The error bars, determined from 4 independent determinations in duplicate represent one 
standard deviation. If one assumes that recovery and detection of PHS-1P and the internal 
standard C17 sphingosine-1P is identical, then the wild type had 230 ng PHS-1P per 40 
OD600 units of cells. 
 
Fig. 7. Dpl1p is an ER resident protein and mutants remain in ER. (A) Localization of 
Dpl1p and mutants. (B) NΔ31CKSN_LLLL is non-functional like CKSN_LLLL in the in 
vivo complementation test. (C) Stability test. JS16 (dpl1Δ) cells carrying plasmids 
expressing FLAG tagged Dpl1p or Dpl1p mutants under own promoter 1: vector; 2: 
DPL1; 3: NΔ31DPL1; 4: NΔ31CKSN_LLLL; 5: CKSN_LLLL were analyzed. Results 
shown are from one experiment representative of three separate experiments. 
 
Fig. 8. Dpl1p unstable mutants are degraded in ER by proteasome. (A) Cycloheximide 
chase analysis of wild-type Dpl1p and NΔ81 mutant. Densitometric measurements of 
Western blots in top and bottom panel were made with the OptiQuant 0.400 program. 
Dpl1p signals (top panel) were normalized to the Dpm1p signals (bottom panel) for each 
time point. Results are shown from one experiment. (B) In vivo complementation test for 
dpl1Δpep4Δ strain bearing DPL1 and unstable mutants on plasmid. (C) Stability test in 
dpl1Δpep4Δ. Cells carrying FLAG tagged DPL1 or DPL1 mutants under own promoter 
on plasmid 1: DPL1; 2: NΔ54DPL1; 3: NΔ81DPL1; 4: H340A; 5: vector were analyzed. 
Results shown are from one experiment representative of three separate experiments (D) 
Stabilization of FLAG tagged Dpl1p unstable mutants by proteasome inhibition. Results 
shown are from one experiment and represent three independent experiments. 
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Fig. 9. Transmembrane domain of Dpl1p is important for activity and oligomerization. 
(A) Activity test. Results are averages ± s.d. of three independent experiments. (B) Blue 
Native PAGE shows Dpl1p as an oligomer. 1 (left panel): dpl1Δ DPL1-FLAG DPL1-
VENUS. Dpl1p detected by anti-VENUS antibody, 2: dpl1Δ DPL1-FLAG DPL1-VENUS. 
Dpl1p is visualized by anti-FLAG antibody, 3 (right panel): dpl1Δ DPL1-FLAG. Dpl1p is 
detected by anti-FLAG antibody, 4: dpl1Δ DPL1CKSN_LLLL-FLAG. The protein is 
detected by anti-FLAG antibody, 5: dpl1Δ + empty vector. (C) Quadruple mutant of 
Dpl1p does not co-immunoprecipitate with wild-type Venus tagged Dpl1p. Protein 
immunoprecipitation by FLAG beads and immunoblotting with either anti-FLAG 
antibody (top) or anti-Venus antibody (bottom panel) (D) Protein immunoprecipitation 
with anti-Venus antibody, followed by immunoblotting with either anti-Venus antibody 
(top) or anti-FLAG antibody (bottom panel). Results shown are from one experiment 
representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I: Important DPL1 residues from parsed homology modelling 
based on the GadB structure 
 
DPL1 residue GadB residue putative function 
Gly235 Ser126 binding of PLP phosphate group 
Thr236 Ser127 binding of PLP phosphate group 
His268 Gln163 stacking of PLP ring 
His340 His341 structurally critical residue for the PF00282 family 
Asp342 Asp243 salt bridge with pyridinium nitrogen of PLP ring 
Asp377 Ser273 binding of PLP phosphate group 
Cys344 Ala245 Van der Waals interaction with PLP ring 
His379 His275 binding of PLP phosphate group 
Lys380 Lys276 covalent binding of PLP (internal aldimine) 
Lys386 Lys282 providing a positive charge for binding of 
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the substrate phosphate 
Ser422 Ser318 binding of PLP phosphate group 
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Table II Plasmids constructed in this study 
 
Plasmid name Yeast 
marker 
Replication 
origin 
Source 
pRS415 Dpl1-Flag LEU2 CEN This study 
pRS415 Dpl1N6A-Flag LEU2 CEN This study 
pRS415 NΔ16Dpl1-Flag LEU2 CEN This study 
pRS415 NΔ31Dpl1-Flag LEU2 CEN This study 
pRS415 NΔ54Dpl1-Flag LEU2 CEN This study 
pRS415 NΔ57Dpl1-Flag LEU2 CEN This study 
pRS415 NΔ81Dpl1-Flag LEU2 CEN This study 
pRS415 Dpl1C65L-Flag LEU2 CEN This study 
pRS415 Dpl1K67L-Flag LEU2 CEN This study 
pRS415 Dpl1S70L-Flag LEU2 CEN This study 
pRS415 Dpl1N71L-Flag LEU2 CEN This study 
pRS415 Dpl1C65K67_LL-Flag LEU2 CEN This study 
pRS415 Dpl1K67S70_LL-Flag LEU2 CEN This study 
pRS415 Dpl1S70N71_LL-Flag LEU2 CEN This study 
pRS415 Dpl1CKSN_LLLL-Flag LEU2 CEN This study 
pRS415 NΔ31Dpl1CKSN_LLLL-Flag LEU2 CEN This study 
pRS415 Dpl1H268A-Flag LEU2 CEN This study 
pRS415 Dpl1H340A-Flag LEU2 CEN This study 
pRS415 Dpl1C344A-Flag LEU2 CEN This study 
pRS415 Dpl1K380A-Flag LEU2 CEN This study 
pRS415 Dpl1K386A-Flag LEU2 CEN This study 
pRS415 Dpl1Y554A-Flag LEU2 CEN This study 
pRS415 Dpl1Y554F-Flag LEU2 CEN This study 
pRS415 Dpl1-Venus LEU2 CEN This study 
pRS415 NΔ31Dpl1-Venus LEU2 CEN This study 
pRS415 NΔ54Dpl1-Venus LEU2 CEN This study 
pRS415 Dpl1K67L-Venus LEU2 CEN This study 
pRS415 Dpl1CKSN_LLLL-Venus LEU2 CEN This study 
pRS415 Dpl1K67S70_LL-Venus LEU2 CEN This study 
pRS415 Dpl1S70N71_LL-Venus LEU2 CEN This study 
pRS415 NΔ31Dpl1CKSN_LLLL-Venus LEU2 CEN This study 
pRS416 Dpl1-Venus URA3 CEN This study 
pESC-Dpl1-Flag URA3 2μ This study 
pESC-Dpl1K380A-Flag URA3 2μ This study 
pESC-Dpl1K386A-Flag URA3 2μ This study 
pESC-NΔ81Dpl1-Flag URA3 2μ This study 
pESC-Dpl1K67L-Flag URA3 2μ This study 
pESC-Dpl1CKSN_LLLL-Flag URA3 2μ This study 
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